Intradigm is developing siRNA-derived cancer therapeutics utilizing its proprietary RNAi technology. Intradigm has led the advancement of siRNA from the test tube to a potent, tissue-targeted, systemically active therapeutic class of gene specific inhibitors. The Company believes that it is the first to demonstrate consistent and reproducible siRNA activity in animal disease models through targeted formulations of siRNA for systemic administration. Based upon the Company’s unique technology and capabilities for developing systemic tissue targeted formulations of siRNA and its ability to achieve efficacy in clinically relevant animal disease models, Intradigm has established an impressive cancer therapeutic product development program with its lead product, ICS-283, now in advanced pre-clinical development.

The Company’s initial focus is on siRNA inhibition of the VEGF pathway targeted to the angiogenic neovasculature. The siRNA formulated product can be used for the treatment of many serious diseases that result from excessive and unwanted angiogenesis, such as colon cancer, lung cancer and many other solid tumors as well as other angiogenesis based diseases such as ocular neovascularization. Intradigm has utilized its proprietary TargeTranÔ technology to develop siRNA formulations which can be systemically delivered and specifically targeted to neovasculature. This targeted, specific sequence siRNA, utilizing innovative layered nanoparticle technology, has been successfully evaluated in several angiogenesis disease animal models with demonstrated efficacy. Intradigm has identified colon cancer as the first indication to evaluate for its systemically administered VEGF pathway siRNA and expects to file an IND within the next 12 months.

In addition to its therapeutic product focus, Intradigm has taken advantage of its portfolio of in vivo siRNA technologies to establish a target validation service business to satisfy the growing demand for utilizing the Company’s powerful capabilities to achieve in vivo activity of RNAi. Intradigm currently has technology effective for a variety of local and systemic administration routes to offer pharmaceutical clients in their quest to validate their vast numbers of novel targets. Intradigm is rapidly expanding its repertoire of relevant animal models in which it has demonstrated siRNA activity for this in vivo target validation service. Intradigm will continue to expand these revenue generating collaborations in parallel with advancing development of its own therapeutic products.